Product Support & Services

National Infusion Center Directory

At Mitsubishi Tanabe Pharma America, Inc., we strive to help people with amyotrophic lateral sclerosis (ALS) access treatment with Radicava® (edaravone). With that goal in mind, we are compiling a comprehensive directory of infusion sites of care throughout the US.

Help patients and providers find your infusion center*

Register Now

FAQs About the National Infusion Center Directory

Who is Mitsubishi Tanabe Pharma America and why is the company compiling a National Infusion Center Directory?
Mitsubishi Tanabe Pharma America is a research-driven pharmaceutical company dedicated to delivering new treatments that address the unmet medical needs of patients in the United States. It is a new and wholly owned US subsidiary of Mitsubishi Tanabe Pharma Corporation, a pharmaceutical company based in Japan. Mitsubishi Tanabe Pharma America has a pipeline of therapeutic products for a diverse array of diseases and conditions, including autoimmune diseases and central nervous system diseases. It is also developing programs to help manage access to treatment. The company is compiling a National Infusion Center Directory to inform prescribing practices about infusion services for their patients.
What are the required qualifications for an infusion center to be included in the National Infusion Center Directory?
To be included in the directory, an infusion site of care must complete and submit the required information on the National Infusion Center Directory Enrollment Form (available here) and fax it to 1-888-782-6157, or enroll online. The infusion center must agree to be contacted by a Mitsubishi Tanabe Pharma America representative at Searchlight Support by mail, fax, email, or telephone for the purposes of reviewing and validating the submitted registration information. All of the information about the infusion center will only be used for inclusion in the National Infusion Center Directory, as outlined in the Terms of Use for the directory. There will be no exchange of fees or remuneration of any kind in exchange for registration or participation in the directory. Infusion centers can update their profile or opt out of the directory at any time by calling Searchlight Support at 1-844-SRCHLGT (1-844-772-4548).
How does the National Infusion Center Directory get information about our infusion center?
An infusion center may provide information about its infusion services by completing an enrollment form and faxing or mailing the completed form to the fax number or address on the enrollment form. Once you enroll your infusion center, a Mitsubishi Tanabe Pharma America representative at Searchlight Support will send an email or fax to confirm receipt of your information and add your infusion center to the directory. All of the information about your infusion center will only be used for inclusion in the National Infusion Center Directory, as outlined in the Terms of Use for the directory. This information will not appear on any website and is subject to the Mitsubishi Tanabe Pharma America Privacy Policy. You can update your profile or opt out of the directory at any time by calling Searchlight Support at 1-844-SRCHLGT (1-844-772-4548).
Our practice or group has many infusion centers in different locations. Do we have to complete an enrollment form for each site of care?
Yes. You need to complete and submit an enrollment form for each infusion center in your practice or group. This is required because the National Infusion Center Directory provides a list of enrolled infusion centers to prescribers that are within a defined geographic area.
How will prescribers utilize the National Infusion Center Directory to get information about our infusion center?
Prescribers will be informed that they can call a Mitsubishi Tanabe Pharma America representative at Searchlight Support and request a list of infusion centers. The representative will conduct a geographic-based search for all infusion centers, based on the zip code and patient insurance information provided by the prescriber. The prescriber will be sent a list of infusion centers in the directory that are within the prescribed geographical area by email, fax, or via the Searchlight Support secure Provider Portal.
What criteria will be used to determine when a prescriber is given information about an infusion center?
A Mitsubishi Tanabe Pharma America representative at Searchlight Support will conduct a geographic-based search for all infusion centers in the directory, based on the zip code and patient insurance information provided by the prescriber. The prescriber will be sent a list of infusion centers that are within the prescribed geographic area by email, fax, or via the Searchlight Support secure Provider Portal. All of the information about your infusion center will only be used for inclusion in the National Infusion Center Directory, as outlined in the Terms of Use for the directory. This information will not appear on any public website and is subject to the Mitsubishi Tanabe Pharma America Privacy Policy. You can update your profile or opt out of the directory at any time by calling Searchlight Support at 1-844-SRCHLGT (1-844-772-4548).
How will you verify receipt of information about our infusion center?
Upon enrollment, a Mitsubishi Tanabe Pharma America representative at will send an email or fax confirming receipt of the information about your infusion center, and notify you if any required information is missing. All of the information about your infusion center will only be used for inclusion in the National Infusion Center Directory, as outlined in the Terms of Use for the directory. This information will not appear on any public website and is subject to the Mitsubishi Tanabe Pharma America Privacy Policy. You can update your profile or opt out of the directory at any time by calling Searchlight Support at 1-844-SRCHLGT (1-844-772-4548).

*No fees or remuneration of any kind have been or will be exchanged for registration, participation, or information provided from the National Infusion Center Directory.

Searchlight Support Infusion Centers

Important Safety Information

Hypersensitivity Reactions

Radicava® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in Radicava®. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported. Patients should be monitored carefully for hypersensitivity reactions, and if they occur, discontinue Radicava®, treat per standard of care, and monitor until the condition resolves.

Sulfite Allergic Reactions

Radicava® contains sodium bisulfite, and may cause allergic type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown, but occurs more frequently in asthmatic people.

Most Common Adverse Reactions

Most common adverse reactions (at least 10% and greater than placebo) are contusion, gait disturbance, and headache.

Pregnancy

Based on animal data, Radicava® may cause fetal harm.

Geriatric Use

No overall differences in safety or effectiveness were observed between patients 65 years of age and older and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Indication

Radicava® is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Please see full Prescribing Information.